Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Hutchison China MediTech Limited    HCM   KYG4672N1016

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/15/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
5530(c) 5710(c) 5640(c) 5610(c) 5540(c) Last
6 841 21 124 12 689 12 078 13 872 Volume
+0.55% +3.25% -1.23% -0.53% -1.25% Change
More quotes
Financials ($)
Sales 2017 240 M
EBIT 2017 -54,5 M
Net income 2017 -
Finance 2017 36,3 M
Yield 2017 -
Sales 2018 271 M
EBIT 2018 -39,0 M
Net income 2018 -
Debt 2018 1,40 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 21,1x
EV / Sales2018 18,9x
Capitalization 5 114 M
More Financials
Company
Hutchison China MediTech Ltd. is a holding company, which engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products.It operates through the following business segments: Drug Research & Development (Drug R&D), Prescription Drug, and... 
Sector
Pharmaceuticals
Calendar
03/01Earnings Release
More about the company
Surperformance© ratings of Hutchison China MediTech L
Trading Rating : - Investor Rating :
More Ratings
Latest news on HUTCHISON CHINA MEDITECH L
2017 HUTCHISON CHINA MEDITECH : Blocklisting Six Monthly Return
2017 HUTCHISON CHINA MEDITECH : Chi-Med Initiates Fruquintinib U.S. Clinical Trials
2017 HUTCHISON CHINA MEDITECH : Chi-Med Initiates Fruquintinib U.S. Clinical Trials
2017 HUTCHISON CHINA MEDITECH : Chi-Med Announces the Closing of U.S. Public Offering..
2017 HUTCHISON CHINA MEDITECH : Chi-Med Initiates FRUTIGA, a Phase III Trial of Fruqu..
2017 HUTCHISON CHINA MEDITECH : Chi-Med Announces the Full Exercise of Underwriters' ..
2017 HUTCHISON CHINA MEDITECH : Chi-Med Announces Pricing of U.S. Public Offering of ..
2017 HUTCHISON CHINA MEDITECH : Chi-Med Announces Proposed Offering of ADSs
2017 HUTCHISON CHINA MEDITECH : Chi Med Initiates FRUTIGA, a Phase III Trial of Fruqu..
2017 HUTCHISON CHINA MEDITECH : Chi-Med Initiates FRUTIGA, a Phase III Trial of Fruqu..
More news
Sector news : Alternative Medicine
01/19 CANADIAN CANNABIS FIRM AURORA IN TAL : sources
01/19 En route to Davos, Macron makes Versailles the place to be
01/19 SHIRE PLC SHIRE PLC : Directorate Change
01/19 At AstraZeneca, fewer drug projects bring big productivity jump
01/18 European shares edge higher as cyclicals back in favour
More sector news : Alternative Medicine
Latest Tweets
04:59aMSU trustee calls for Simon to step down over Nassar.
3
04:38aMichigan State University trustee Mitch Lyons calls for Lou Anna Simon ‘to re..
1
04:28aMSU board member Mitch Lyons calls for embattled president Lou Anna Simon to ..
3
03:59a#BREAKING: MSU board member Mitch Lyons calls for embattled university presid..
7
03:58aMSU board member Mitch Lyons calls for embattled president Lou Anna Simon to ..
11
More tweets
Qtime:443
News from SeekingAlpha
2017 HUTCHISON CHINA MEDITECH : Outlook For 2018
2017 JONATHAN FAISON POSITIONS FOR 2018 : Faster FDA Approval, Emerging Sector In Chi..
2017 WEEK IN REVIEW : Fosun Signs $125 Million Deal For Ardelyx IBS Treatment
2017 Chi-Med initiates Fruquintinib U.S. clinical trials
2017 WEEK IN REVIEW : China Resources Pharma Files For $369 Million China Life Scienc..
Chart HUTCHISON CHINA MEDITECH L
Duration : Period :
Hutchison China MediTech L Technical Analysis Chart | HCM | KYG4672N1016 | 4-Traders
Technical analysis trends HUTCHISON CHINA MEDITECH L
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 40,0 $
Spread / Average Target -48%
EPS Revisions
Managers
NameTitle
Christian Hogg Chief Executive Officer & Executive Director
Chi Keung To Executive Chairman
Chig Fung Cheng Chief Financial Officer & Executive Director
Wei Guo Su Executive Director, Chief Scientific Officer & EVP
Edith Shih Secretary & Non-Executive Director
Sector and Competitors